Epigenetics is converting to Open Access
The journal offers a home for research dedicated to the study of epigenetics mechanisms and their role in diverse biological processes. The journal publishes research relevant to a wide variety of medical and biological issues and provides a forum to strengthen discussion on how human behaviour and social and environmental influences can have epigenetics consequences.
Epigenetics launched in 2006 and in a relatively short period of time we have seen the research landscape change dramatically. We have seen the uptake of open access publishing in the journal increase in the recent years and – listening to the needs of our authors and readers – have made the decision to convert the journal to open access from 2023.
By making Epigenetics open access, research published in the journal will be available to the widest possible audience and therefore can make a greater contribution to the epigenetics community. From 7th June, all manuscripts submitted to the journal will, if accepted, be required to pay an article publishing charge (APC) which can be covered by an author’s funder or institution. We look forward to receiving your submissions and welcome your support in this exciting new open access chapter for the journal.
Epigenetics is particularly interested in receiving manuscripts on:
DNA methylation
Nucleosome positing and modification
Gene silencing
Imprinting
Chromatin remodeling
Non-coding RNA
Dosage compensation
Epigenetic therapy and diagnostics
Cancer epigenetics
Neuroepigenetics
Editor-In-Chief
Dr Manel Esteller graduated in Medicine from the University of Barcelona, where he also obtained his Ph.D. degree specialising in cancer molecular genetics. He is the Director of the Josep Carreras Leukaemia Research Institute (IJC), Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor.
His current research is devoted to the establishment of the epigenome and epitranscriptome maps of normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy.
Author of more than 600 original publications in peer-reviewed scientific journals, 24 of them categorized as “Highly Cited Paper”. Dr. Esteller is considered among the Top 0.01% of World Scientists based on Impact by both the Stanford University (METRICS) and the Web of Science Group-Clarivate Analytics. In 2021 he was been elected as Member of the Academia Europaea and of the European Academy of Sciences.
Why publish open access?
Increase the visibility and readership of your research by publishing in a fully open access journal.
Make an impact beyond the academy by making your article accessible to anyone, anywhere (including readers in industry and even policy-makers).
Freely share your work with no restrictions or paywall.
Retain ownership of your research through our unrestrictive publishing agreements.
Discounts and waivers for researchers in developing countries are available. The journal will also consider requests for discretionary APC waivers. Find out if your institution or country has an open access agreement to publish with us.